Contributions
Abstract: P1019
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: Limitations in hand and arm functioning is a major problem in multiple sclerosis (MS) patients affecting up to 76% of patients. It affects activities of daily living (ADL) and is associated with high societal costs due to loss of work and utilization of care.
Recently, the Arm function in MS Questionnaire (AMSQ) was developed using IRT methods. The AMSQ is the first MS specific patient reported instrument to measure limitations in hand and arm functioning. The AMSQ was developed to be used in treatment trials, natural cohort studies, and daily clinical practice.
The AMSQ was originally developed in Dutch and so far translated into five languages (i.e. English, German, Spanish, French, and Italian). The aim of the present study was to evaluate cross-cultural validity of the instrument in these languages.
Methods: We performed differential item functioning (DIF) analyses, using 'language' as the group variable. To detect DIF, logistic regression and item response theory (IRT) principles were applied, using the R package lordif. Multiple logistic regression models were evaluated, aiming to detect uniform and non-uniform DIF. We used a pseudo R2 value of 0.02 or more as the DIF threshold.
Results: Overall 995 male and female patients with all subtypes (age 18 - 91 years) completed the AMSQ.
The DIF analysis for the whole dataset showed no uniform or non-uniform DIF on any of the 31 items. All R2 values were below 0.02.
Conclusion: The results indicate that all 31 items of the AMSQ have the same meaning to MS patients. The AMSQ can be used to measure hand and arm functioning in the Dutch, Spanish, German, French, Italian and English version. It enables the use of the AMSQ in international studies.
Future directions: In the future the itembank will be available as a computer adaptive test (CAT). Recently, a ten-item short form of the AMSQ was developed.
Disclosure: Source of funding: none
Kalkers NF: nothing to disclose
Galan I:nothing to disclose
Kerbrat A: nothing to disclose
Tacchino A:nothing to disclose
Kamm CP: has received honoraria for lectures as well as research support from Biogen, Novartis, Almirall, Bayer Schweiz AG, Teva, Merck, Sanofi Genzyme, Roche, Celgene and the Swiss MS Society (SMSG).
O'Connell K: received a travel and educational grant from Novartis to attend ECTRIMS 2017
McGuigan C: received research funding and/or honoraria from Actelion, Biogen, Merck, Novartis, Roche and Sanofi Genzyme.
Gargallo M: nothing to disclose
Edan G: nothing to disclose
Montalban X: speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Actelion, Bayer, Biogen, Celgene, Hoffmann-La Roche, Merck, Novartis, Oryzon Genomics, Sanofi-Genzyme and Teva Pharmaceutical.”
Uitdehaag BMJ:: consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and Teva
Mokkink LB: nothing to disclose
Abstract: P1019
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: Limitations in hand and arm functioning is a major problem in multiple sclerosis (MS) patients affecting up to 76% of patients. It affects activities of daily living (ADL) and is associated with high societal costs due to loss of work and utilization of care.
Recently, the Arm function in MS Questionnaire (AMSQ) was developed using IRT methods. The AMSQ is the first MS specific patient reported instrument to measure limitations in hand and arm functioning. The AMSQ was developed to be used in treatment trials, natural cohort studies, and daily clinical practice.
The AMSQ was originally developed in Dutch and so far translated into five languages (i.e. English, German, Spanish, French, and Italian). The aim of the present study was to evaluate cross-cultural validity of the instrument in these languages.
Methods: We performed differential item functioning (DIF) analyses, using 'language' as the group variable. To detect DIF, logistic regression and item response theory (IRT) principles were applied, using the R package lordif. Multiple logistic regression models were evaluated, aiming to detect uniform and non-uniform DIF. We used a pseudo R2 value of 0.02 or more as the DIF threshold.
Results: Overall 995 male and female patients with all subtypes (age 18 - 91 years) completed the AMSQ.
The DIF analysis for the whole dataset showed no uniform or non-uniform DIF on any of the 31 items. All R2 values were below 0.02.
Conclusion: The results indicate that all 31 items of the AMSQ have the same meaning to MS patients. The AMSQ can be used to measure hand and arm functioning in the Dutch, Spanish, German, French, Italian and English version. It enables the use of the AMSQ in international studies.
Future directions: In the future the itembank will be available as a computer adaptive test (CAT). Recently, a ten-item short form of the AMSQ was developed.
Disclosure: Source of funding: none
Kalkers NF: nothing to disclose
Galan I:nothing to disclose
Kerbrat A: nothing to disclose
Tacchino A:nothing to disclose
Kamm CP: has received honoraria for lectures as well as research support from Biogen, Novartis, Almirall, Bayer Schweiz AG, Teva, Merck, Sanofi Genzyme, Roche, Celgene and the Swiss MS Society (SMSG).
O'Connell K: received a travel and educational grant from Novartis to attend ECTRIMS 2017
McGuigan C: received research funding and/or honoraria from Actelion, Biogen, Merck, Novartis, Roche and Sanofi Genzyme.
Gargallo M: nothing to disclose
Edan G: nothing to disclose
Montalban X: speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Actelion, Bayer, Biogen, Celgene, Hoffmann-La Roche, Merck, Novartis, Oryzon Genomics, Sanofi-Genzyme and Teva Pharmaceutical.”
Uitdehaag BMJ:: consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and Teva
Mokkink LB: nothing to disclose